Jun 15, 2023 / 05:40PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Great. Good morning, everyone. Thanks for joining us. Really pleased to have with us the Kronos team. We have Norbert Bischofberger, President and CEO; Yasir Al-Wakeel, CFO and Head of Corporate Development; and Jorge DiMartino...
Charles Lin - Kronos Bio, Inc. - SVP of Biology
I'm Charles.
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Actually, Charles. sorry.
Charles Lin - Kronos Bio, Inc. - SVP of Biology
Jorge couldn't make it.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPYes. Yes. Yes. So maybe to start here. KB-0742, your CDK inhibitor, is the first molecule to emerge from your platform. Can you start by walking through the key takeaways for the first -- from the first data release that you provided as well as the rationale for your Phase II dose selection?